Del-etion of Microvesicles From the Circulation
2012; Lippincott Williams & Wilkins; Volume: 125; Issue: 13 Linguagem: Inglês
10.1161/circulationaha.112.094920
ISSN1524-4539
AutoresPierre‐Emmanuel Rautou, Nigel Mackman,
Tópico(s)Autophagy in Disease and Therapy
ResumoHomeCirculationVol. 125, No. 13Del-etion of Microvesicles From the Circulation Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBDel-etion of Microvesicles From the Circulation Pierre-Emmanuel Rautou, MD, PhD and Nigel Mackman, PhD Pierre-Emmanuel RautouPierre-Emmanuel Rautou From the Department of Medicine, Division of Hematology & Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill. and Nigel MackmanNigel Mackman From the Department of Medicine, Division of Hematology & Oncology, McAllister Heart Institute, University of North Carolina at Chapel Hill. Originally published2 Mar 2012https://doi.org/10.1161/CIRCULATIONAHA.112.094920Circulation. 2012;125:1601–1604Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2012: Previous Version 1 Microvesicles (also called microparticles) have become a hot topic recently and transport proteins, mRNA, and microRNA.1–3 They have been proposed to play roles in numerous processes, including coagulation, inflammation, immune response, cell activation, and cancer.1–3 Microvesicles are small (0.1–1 μm) membrane vesicles that are released from activated and apoptotic cells. They contain proteins from their parental cell and are characterized by surface exposure of negatively charged phospholipids, such as phosphatidylserine. Platelets are the primary source of microvesicles in the circulation of healthy individuals, although other cells also release microvesicles. Increased levels of microvesicles are observed in a variety of cardiovascular diseases, including unstable angina, atherosclerosis, and inflammatory vascular diseases. Some microvesicle populations are considered as surrogate biomarkers of vascular disorders and of thrombotic risk.2,3Article see p 1664The steady-state level of microvesicles in the circulation reflects a balance between microvesicle generation and clearance. Numerous studies have analyzed the mechanisms of microvesicle formation.1 Stimulation of cells leads to elevated levels of intracellular Ca2+, which results in increased phosphatidylserine on the cell surface, membrane blebbing, and subsequent shedding of microvesicles.1 The importance of phosphatidylserine exposure on platelets and possibly microvesicles in hemostasis is demonstrated by Scott syndrome, a rare bleeding disorder associated with a defect in phosphatidylserine externalization and in microvesicle generation.1 Recently, it was reported that Scott syndrome patients have a mutation in a bidirectional, nonselective Ca2+-dependent channel called TMEM16F.4In this issue of Circulation, Dasgupta and colleagues5 describe a new pathway of microvesicle clearance from the circulation that involves binding of phosphatidylserine-positive microvesicles to endothelial cells (Figure). Previously, Dasgupta and colleagues6 reported that the major pathway for the removal of microvesicles from the circulation was via binding to splenic macrophages (Figure). This pathway requires the presence of a glycoprotein called lactadherin (also known as milk fat globule-epidermal growth factor 8), which is secreted by activated macrophages and immature dendritic cells.7 Lactadherin is a bifunctional protein that contains both discoidin I–like domains, which bind to phosphatidylserine on the surface of apoptotic cells and microvesicles, and a tripeptide Arg-Gly-Asp (RGD) motif, which binds to cellular integrins, such as αvβ3. In vitro studies demonstrated that lactadherin enhances platelet microvesicle binding and phagocytosis by macrophages.6 Lactadherin is not detected free in plasma of healthy individuals but has been found on the surface of platelet microvesicles.6 Interestingly, soluble lactadherin does not bind to αvβ3-positive cells (Dr G. Gilbert, unpublished data, 2008), which suggests that binding of lactadherin to phosphatidylserine-positive microvesicles changes its conformation to allow binding to αvβ3. Taken together, these results indicate that lactadherin bridges the binding of phosphatidylserine-positive microvesicles to splenic macrophages and facilitates their removal from the circulation. Under normal conditions, this appears to be a major pathway for microvesicle clearance from the circulation. Indeed, lactadherin-deficient mice have higher basal levels of circulating microvesicles than control mice, which results in a hypercoagulable state.6 In addition, a deficiency of lactadherin in bone marrow cells results in increased levels of circulating microvesicles in a mouse model of atherosclerosis.8Download figureDownload PowerPointFigure. Pathways for clearance of microvesicles from the circulation. In normal conditions, the lactadherin pathway mediates clearance of microvesicles. Macrophages in the spleen secrete lactadherin, and this facilitates capture of circulating microvesicles. In endotoxemia, the developmental endothelial locus-1 (Del-1) pathway mediates clearance of microvesicles. We speculate that this pathway is turned on by the increased αvβ3 expression on the surface of endothelial cells. Activated endothelial cells also express adhesion molecules, such as P-selectin, which can capture leukocyte microvesicles that contain P-selectin glycoprotein ligand-1 (PSGL-1). LMV indicates leukocyte microvesicle; PMV, platelet microvesicle.The new pathway of microvesicle clearance described by Dasgupta and colleagues5 involves endothelial cells and a bridging glycoprotein called developmental endothelial locus-1 (Del-1). A previous study reported uptake of microvesicles by endothelial cells in the liver by a phosphatidylserine-dependent mechanism.9 Del-1 was discovered as an αvβ3 binding protein that regulates angiogenesis during embryogenesis.10 Del-1 is secreted by endothelial cells and, similar to lactadherin, has discoidin I–like domains and an RGD motif that mediate binding to both phosphatidylserine on microvesicles and αvβ3 on cells. In adult mice, Del-1 mRNA is expressed in the lungs and brain, with no expression in the liver or spleen.11 Interestingly, Dasgupta and colleagues5 found Del-1 in the plasma of healthy individuals. Moreover, a significant number of microvesicles from platelets and red blood cells bound Del-1 in flow cytometry experiments, whereas only a small number of microvesicles from monocytes and endothelial cells were positive. Del-1 is likely binding to phosphatidylserine on microvesicles in a similar manner to lactadherin; however, it is unclear why Del-1 appears to bind selectively to different populations of microvesicles. One might have expected a higher percentage of Del-1 binding to microvesicles derived from endothelial cells, because these cells express Del-1. In addition, Del-1 has been shown to bind the leukocyte integrin αLβ2 (also called CD11a).11 Therefore, one could also have expected higher binding of Del-1 to microvesicles derived from monocytes. Importantly, in contrast to the results observed with lactadherin-deficient mice, Del-1–deficient mice do not have increased basal levels of microvesicles compared with controls.5 The authors hypothesize that this lack of change in basal microvesicle level may be caused by compensation by other pathways.Dasgupta and colleagues5 found that binding of platelet microvesicles to cultured human umbilical vein endothelial cells and human microvascular endothelial cells was inhibited by blocking phosphatidylserine or αvβ3. Similar results were observed with microvesicles from red blood cells. However, no studies were presented with microvesicles from monocytes or endothelial cells, which have lower levels of Del-1 binding in the circulation. Next, fluorescently labeled human platelet microvesicles were injected into mice, and their uptake was measured in endothelial cells in various tissues. Del-1 deficiency led to a 50% reduction in microvesicle uptake by lung and liver endothelial cells but no change in uptake by splenic endothelial cells.5 These differences may reflect heterogeneous αvβ3 expression in the endothelium of the different tissues. For instance, relatively high levels of αvβ3 are observed in lung microvascular endothelium, with weaker expression in other organs.12 Despite differences in processing of these exogenous microvesicles, as noted above, there was no change in levels of endogenous microvesicles in Del-1–deficient mice. Therefore, these results should be interpreted cautiously.Endotoxemia leads to increased levels of circulating microvesicles in mice.3 Interestingly, administration of lipopolysaccharide dramatically decreases lactadherin expression in the spleen, which would limit the effectiveness of this pathway to clear the elevated levels of microvesicles.7 Dasgupta and colleagues5 determined whether a deficiency in Del-1 affected levels of microvesicles after challenge with lipopolysaccharide. They found significantly higher levels of microvesicles in the plasma of Del-1–deficient mice compared with controls. This result suggests that the Del-1 clearance pathway may be "turned on" during pathological conditions that are associated with elevated levels of circulating microvesicles. At present, it is not clear how the Del-1 clearance pathway is upregulated, but it may be by increased expression of αvβ3. Indeed, αvβ3 expression is increased in endothelial cells exposed to inflammatory stimuli, such as tumor necrosis factor-α.13Other molecules beside lactadherin and Del-1 bind to phosphatidylserine-positive microvesicles. For instance, the bridging molecule called growth-arrest-specific 6 (also known as GAS6) can bind to phosphatidylserine on cells and the phagocyte receptor tyrosine kinase MER.14 However, we did not find a difference in the number of phosphatidylserine-positive microvesicles between growth-arrest-specific 6–deficient mice and controls either at baseline or after lipopolysaccharide challenge (Burnier L, Lee R, Angelillo-Scherrer A, and Mackman N, unpublished data, 2011). β2-Glycoprotein I is another phosphatidylserine binding protein that binds platelet microvesicles and promotes their phagocytosis by macrophages in a phosphatidylserine-dependent manner.15 Ligand-receptor interactions may also contribute to microvesicle clearance. Binding of monocyte-derived microvesicles to activated platelets was shown to be dependent on both phosphatidylserine and P-selectin glycoprotein ligand-1.16 A similar dual interaction may occur between monocyte microvesicles and activated endothelium (Figure). Therefore, we propose a general mechanism for microvesicle uptake by macrophages and endothelial cells that involves both binding via phosphatidylserine bridging molecules, such as lactadherin and Del-1, to αvβ3 and other ligand-receptor interactions. The relative contribution of each of these different pathways to microvesicle clearance from the circulation remains to be determined.Interestingly, different organs have been implicated in microvesicle clearance depending on the cell origin of the microvesicles (Table).5,6,9,17,18 This may be because of differences in protein and lipid composition of microvesicles from different cell types. Interestingly, splenectomy is associated with increased levels of circulating red blood cell and leukocyte microvesicles in patients.19 This observation is consistent with the lactadherin-macrophage clearance pathway operating mainly in the spleen. Moreover, removal of the spleen in a xenograft tumor model was associated with increased levels of tumor-derived microvesicles.18 In rodent studies, microvesicles are cleared very rapidly (Table). In contrast, platelet microvesicles were cleared more slowly in patients receiving platelet transfusions.20 Importantly, efficient clearance of circulating microvesicles is needed in pathological conditions. One study found that a 30-minute exposure to second-hand smoke was associated with an increase in circulating endothelial cell–derived microvesicles for up to 24 hours, which may reflect ongoing endothelial cell activation and/or a defect in clearance.2Table. Studies Assessing Clearance of Microvesicles In VivoCell Origin of MVsOrgans ImplicatedMain Cells ImplicatedMolecules ImplicatedKinetics of MV ClearanceReferencesSpleenLiverLungsKidneysPlatelet MVs+++Not assessedNot assessedNot assessedMacrophagesLactadherinUptake assessed 5 min after injection6Platelet MVs++++++Not assessedEndothelial cellsDel-1 in lungs and liver but not in spleenUptake assessed 5 min after injection5Erythrocyte MVs+/−++++/−+/−In the liver: 92% by Kupffer cellsPhosphatidylserineWithin 5 min, 80% of MVs are cleared from the circulation9Endothelial cell MVs+++++++−Monocyte/ macrophages plus other undetermined cellsNot assessedUptake assessed 5 min after injection17Tumor cell MVs++Not assessedNot assessedNot assessedNot assessedNot assessedDetectable in plasma up to 30 min after injection18MV indicates microvesicle; Del-1, developmental endothelial locus-1.The findings by Dasgupta and colleagues5 have implications beyond the field of microvesicle clearance. These investigators demonstrate that platelet microvesicles can interact with endothelial cells in vivo. This result is highly significant because numerous in vitro and ex vivo studies have shown that various microvesicles can modulate endothelial cell biology by inducing endothelial proliferation, inflammatory phenotype, or dysfunction.2 The in vivo relevance of these studies was so far somewhat uncertain.In conclusion, the present study not only highlights a new mechanism for the clearance of circulating microvesicles but also sheds new light on in vitro studies showing that different microvesicles can regulate endothelial cell functions. Because the endothelium is positioned at the interface of blood and tissues, it plays a key role in interpreting signals delivered via the circulation. We speculate that different microvesicles may be targeted to endothelial cells in various organs by specific interactions, similar to the delivery of letters using zip codes. Further studies are needed to better understand how microvesicles modulate endothelial cell biology in vivo.AcknowledgmentsWe would like to thank our colleagues for critical reading of the manuscript.Sources of FundingThis work was supported by the Philippe Foundation (to Dr Rautou) and a grant (HL095096; to Dr Mackman) from the National Institutes of Health.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Nigel Mackman, PhD, University of North Carolina at Chapel Hill; Chapel Hill, NC. E-mail [email protected]unc.eduReferences1. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol. 2011; 31:15–26.LinkGoogle Scholar2. Rautou PE, Vion AC, Amabile N, Chironi G, Simon A, Tedgui A, Boulanger CM. Microparticles, vascular function, and atherothrombosis. Circ Res. 2011; 109:593–606.LinkGoogle Scholar3. Owens AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011; 108:1284–1297.LinkGoogle Scholar4. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature. 2010; 468:834–838.CrossrefMedlineGoogle Scholar5. Dasgupta SK, Le A, Chavakis T, Rumbaut RE, Thiagarajan P. Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium. Circulation. 2012; 125:1664–1672.LinkGoogle Scholar6. Dasgupta SK, Abdel-Monem H, Niravath P, Le A, Bellera RV, Langlois K, Nagata S, Rumbaut RE, Thiagarajan P. Lactadherin and clearance of platelet-derived microvesicles. Blood. 2009; 113:1332–1339.CrossrefMedlineGoogle Scholar7. Aziz M, Jacob A, Matsuda A, Wang P. Review: milk fat globule-EGF factor 8 expression, function and plausible signal transduction in resolving inflammation. Apoptosis. 2011; 16:1077–1086.CrossrefMedlineGoogle Scholar8. Ait-Oufella H, Kinugawa K, Zoll J, Simon T, Boddaert J, Heeneman S, Blanc-Brude O, Barateau V, Potteaux S, Merval R, Esposito B, Teissier E, Daemen MJ, Leseche G, Boulanger C, Tedgui A, Mallat Z. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation. 2007; 115:2168–2177.LinkGoogle Scholar9. Willekens FL, Werre JM, Kruijt JK, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, van den Bos AG, Bosman GJ, van Berkel TJ. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors. Blood. 2005; 105:2141–2145.CrossrefMedlineGoogle Scholar10. Hidai C, Zupancic T, Penta K, Mikhail A, Kawana M, Quertermous EE, Aoka Y, Fukagawa M, Matsui Y, Platika D, Auerbach R, Hogan BL, Snodgrass R, Quertermous T. Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. Genes Dev. 1998; 12:21–33.CrossrefMedlineGoogle Scholar11. Choi EY, Chavakis E, Czabanka MA, Langer HF, Fraemohs L, Economopoulou M, Kundu RK, Orlandi A, Zheng YY, Prieto DA, Ballantyne CM, Constant SL, Aird WC, Papayannopoulou T, Gahmberg CG, Udey MC, Vajkoczy P, Quertermous T, Dimmeler S, Weber C, Chavakis T. Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment. Science. 2008; 322:1101–1104.CrossrefMedlineGoogle Scholar12. Singh B, Fu C, Bhattacharya J. Vascular expression of the alpha(v)beta(3)-integrin in lung and other organs. Am J Physiol Lung Cell Mol Physiol. 2000; 278:L217–L226.CrossrefMedlineGoogle Scholar13. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med. 1998; 4:408–414.CrossrefMedlineGoogle Scholar14. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol. 2007; 7:964–974.CrossrefMedlineGoogle Scholar15. Abdel-Monem H, Dasgupta SK, Le A, Prakasam A, Thiagarajan P. Phagocytosis of platelet microvesicles and beta2- glycoprotein I. Thromb Haemost.2010; 104:335–341.CrossrefMedlineGoogle Scholar16. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005; 106:1604–1611.CrossrefMedlineGoogle Scholar17. Al Faraj A, Gazeau F, Wilhelm C, Devue C, Guerin CL, Pechoux C, Paradis V, Clement O, Boulanger CM, Rautou PE. Endothelial cell-derived microparticles loaded with iron oxide nanoparticles: feasibility of MR imaging monitoring in mice. Radiology. February13, 2012. doi:10.1148/radiol.11111329. http://radiology.rsna.org/content/early/2012/02/09/radiol.11111329.fullAccessed March 10, 2012.CrossrefMedlineGoogle Scholar18. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis JL. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008; 6:1517–1524.CrossrefMedlineGoogle Scholar19. Fontana V, Jy W, Ahn ER, Dudkiewicz P, Horstman LL, Duncan R, Ahn YS. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res. 2008; 122:599–603.CrossrefMedlineGoogle Scholar20. Rank A, Nieuwland R, Crispin A, Grutzner S, Iberer M, Toth B, Pihusch R. Clearance of platelet microparticles in vivo. Platelets. 2011; 22:111–116.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Luu S, Woolley I and Andrews R (2020) Platelet phenotype and function in the absence of splenic sequestration (Review), Platelets, 10.1080/09537104.2020.1732322, 32:1, (47-52), Online publication date: 2-Jan-2021. O'Dea K, Tan Y, Shah S, V Patel B, C Tatham K, Wilson M, Soni S and Takata M (2020) Monocytes mediate homing of circulating microvesicles to the pulmonary vasculature during low‐grade systemic inflammation, Journal of Extracellular Vesicles, 10.1080/20013078.2019.1706708, 9:1, (1706708), Online publication date: 1-Sep-2020. Baranova A, Maltseva D and Tonevitsky A (2018) Adipose may actively delay progression of NAFLD by releasing tumor‐suppressing, anti‐fibrotic miR ‐122 into circulation , Obesity Reviews, 10.1111/obr.12765, 20:1, (108-118), Online publication date: 1-Jan-2019. Hernández-Gea V, De Gottardi A, Leebeek F, Rautou P, Salem R and Garcia-Pagan J (2019) Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis, Journal of Hepatology, 10.1016/j.jhep.2019.02.015, 71:1, (175-199), Online publication date: 1-Jul-2019. Payancé A, Silva‐Junior G, Bissonnette J, Tanguy M, Pasquet B, Levi C, Roux O, Nekachtali O, Baiges A, Hernández‐Gea V, Laouénan C, Lebrec D, Albuquerque M, Paradis V, Moreau R, Valla D, Durand F, Boulanger C, Garcia‐Pagan J and Rautou P (2018) Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis, Hepatology, 10.1002/hep.29903, 68:4, (1508-1518), Online publication date: 1-Oct-2018. Ridger V, Boulanger C, Angelillo-Scherrer A, Badimon L, Blanc-Brude O, Bochaton-Piallat M, Boilard E, Buzas E, Caporali A, Dignat-George F, Evans P, Lacroix R, Lutgens E, Ketelhuth D, Nieuwland R, Toti F, Tuñon J, Weber C, Hoefer I, Lip G, Werner N, Shantsila E, ten Cate H, Thomas M and Harrison P (2017) Microvesicles in vascular homeostasis and diseases, Thrombosis and Haemostasis, 10.1160/TH16-12-0943, 117:07, (1296-1316), . Liu Y, He Z, Zhang Y, Dong Z, Bi Y, Kou J, Zhou J and Shi J (2016) Dissimilarity of increased phosphatidylserine-positive microparticles and associated coagulation activation in acute coronary syndromes, Coronary Artery Disease, 10.1097/MCA.0000000000000368, 27:5, (365-375), Online publication date: 1-Aug-2016. Rhim T and Lee K (2016) Exosome and polymersome for potential theranostic applications, Macromolecular Research, 10.1007/s13233-016-4045-1, 24:7, (577-586), Online publication date: 1-Jul-2016. Kimmig L and Palevsky H (2016) Review of the Association between Splenectomy and Chronic Thromboembolic Pulmonary Hypertension, Annals of the American Thoracic Society, 10.1513/AnnalsATS.201512-826FR, 13:6, (945-954), Online publication date: 1-Jun-2016. Moon P, Lee J, Cho Y, Lee S, Jung J, Chae Y, Bae H, Kim Y, Kim I, Park H and Baek M (2016) Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection, Clinical Cancer Research, 10.1158/1078-0432.CCR-15-0654, 22:7, (1757-1766), Online publication date: 1-Apr-2016. Ayers L, Nieuwland R, Kohler M, Kraenkel N, Ferry B and Leeson P (2015) Dynamic microvesicle release and clearance within the cardiovascular system: triggers and mechanisms, Clinical Science, 10.1042/CS20140623, 129:11, (915-931), Online publication date: 1-Dec-2015. Zhu X, You Y, Li Q, Zeng C, Fu F, Guo A, Zhang H, Zou P, Zhong Z, Wang H, Wu Y, Li Q, Kong F and Chen Z (2014) BCR-ABL1–positive microvesicles transform normal hematopoietic transplants through genomic instability: implications for donor cell leukemia, Leukemia, 10.1038/leu.2014.51, 28:8, (1666-1675), Online publication date: 1-Aug-2014. Hian Tan K, Sim Tan S, Sze S, Ryan Lee W, Jack Ng M and Kiang Lim S (2014) Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles, American Journal of Obstetrics and Gynecology, 10.1016/j.ajog.2014.03.038, 211:4, (380.e1-380.e13), Online publication date: 1-Oct-2014. Lemoinne S, Thabut D, Housset C, Moreau R, Valla D, Boulanger C and Rautou P (2014) The emerging roles of microvesicles in liver diseases, Nature Reviews Gastroenterology & Hepatology, 10.1038/nrgastro.2014.7, 11:6, (350-361), Online publication date: 1-Jun-2014. Wang J, Aikawa E and Aikawa M (2013) Leukocyte-Derived Microparticles as Proinflammatory Mediators in Atherosclerosis, Journal of the American College of Cardiology, 10.1016/j.jacc.2013.04.054, 62:16, (1442-1445), Online publication date: 1-Oct-2013. Boisramé-Helms J, Delabranche X, Toti F and Meziani F (2012) Nature et signification des microparticules dans le sepsisThe nature and significance of microparticles in sepsis, Réanimation, 10.1007/s13546-012-0537-y, 22:S2, (343-351), Online publication date: 1-Jan-2013. Rautou P and Mackman N (2014) Microvesicles as risk markers for venous thrombosis, Expert Review of Hematology, 10.1586/ehm.12.74, 6:1, (91-101), Online publication date: 1-Feb-2013. Levin C, Koren A, Rebibo-Sabbah A, Koifman N, Brenner B and Aharon A (2018) Extracellular Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional Status and Ineffective Erythropoiesis, Frontiers in Physiology, 10.3389/fphys.2018.01214, 9 April 3, 2012Vol 125, Issue 13 Advertisement Article InformationMetrics © 2012 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.112.094920PMID: 22388321 Originally publishedMarch 2, 2012 Keywordsendothelial functionendotheliumplateletsclearancemicroparticlesEditorialsPDF download Advertisement SubjectsEndothelium/Vascular Type/Nitric OxidePlateletsVascular Biology
Referência(s)